Ascentage Pharma to Present Lisaftoclax Data at ASH 2025
In a registrational Phase II study of 72 evaluable patients with relapsed/refractory CLL/SLL after BTK inhibitor exposure, lisaftoclax monotherapy...
Fulcrum to Present New Sickle Cell Data for Pociredir at ASH
Early Phase 1b signals from Fulcrum’s PIONEER study suggest pociredir, an oral EED inhibitor, increases fetal hemoglobin to levels...
New Obefazimod Trial Data Improves Ulcerative Colitis Life
In pooled 8‑week induction data from the Phase 3 ABTECT‑1 and ABTECT‑2 trials in moderate‑to‑severe ulcerative colitis, 37% of...
TransCon PTH: Latest 3-Year Renal Data for Adults Unveiled
Three-year follow-up from Ascendis Pharma’s PaTH Forward (Phase 2) and PaTHway (Phase 3) trials in adults with chronic hypoparathyroidism...
WAVE Trial: WRAPSODY 24-Month Efficacy Results for AVG
Topline data: In the non-randomized AVG cohort (n=112) of Merit Medical’s WAVE trial, WRAPSODY Cell-Impermeable Endoprosthesis achieved a 6-month...
Geltq Launches Trial for New Oil-Soluble Drug Platform
Gelteq has initiated a preclinical animal study with the Monash University Institute of Pharmaceutical Sciences to evaluate a gel-based...
NodThera Doses First Patients in New GLP-1 Combo Trial
Prior clinical data for NT-0796 reported rapid reductions of about 80% in IL-6, fibrinogen, and hsCRP in patients at...
Biomea Doses First Patient in Phase I Study of Oral GLP-1
In preclinical studies, once-daily oral dosing of BMF-650 in obese cynomolgus monkeys produced dose-dependent reductions in food intake and...
IN8bio T Cell Data Shows B Cell Depletion for Autoimmune
IN8bio reported preclinical data showing that its pan-γδ T cell engager, INB-619, achieved complete B cell depletion in systemic...
Rapt Therapeutics Starts Phase 2b Trial for Food Allergies
RAPT Therapeutics has opened enrollment for prestIgE, a randomized, double-blind, placebo-controlled Phase 2b study of ozureprubart (formerly RPT904) in...